Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral Semaglutide in Healthy Chinese Subjects
NCT04016974Phase 1Completed
- Sponsor
- Novo Nordisk
- Start
- Oct 2019
- Primary completion
- Jan 2021
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing Oral Semaglutide with Placebo (2 arms). Primary endpoint: Area under the semaglutide concentration-time curve during a dosing interval at steady state at Day 84. Started Oct 2019; status: completed.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT04016974.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04016974.